INMED PHARMACEUTICALS INC (INM) Stock Price & Overview
NASDAQ:INM • CA4576377002
Current stock price
The current stock price of INM is 0.6916 USD. Today INM is down by -9.12%. In the past month the price decreased by -10.47%. In the past year, price decreased by -63.06%.
INM Key Statistics
- Market Cap
- 2.019M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.08
- Dividend Yield
- N/A
INM Stock Performance
INM Stock Chart
INM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to INM. When comparing the yearly performance of all stocks, INM is a bad performer in the overall market: 95.16% of all stocks are doing better.
INM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INM. INM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
INM Earnings
INM Forecast & Estimates
INM Groups
Sector & Classification
INM Financial Highlights
Over the last trailing twelve months INM reported a non-GAAP Earnings per Share(EPS) of -4.08. The EPS increased by 70.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.48% | ||
| ROE | -79.94% | ||
| Debt/Equity | 0 |
INM Ownership
INM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 858.976B | ||
| JNJ | JOHNSON & JOHNSON | 20.2 | 567.035B | ||
| MRK | MERCK & CO. INC. | 22.49 | 286.006B | ||
| PFE | PFIZER INC | 9.03 | 152.277B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.06 | 116.079B | ||
| ZTS | ZOETIS INC | 16.38 | 48.642B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.82 | 26.311B | ||
| VTRS | VIATRIS INC | 5.33 | 15.302B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.67 | 12.151B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.022B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.67B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.269B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.75 | 3.995B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INM
Company Profile
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Company Info
IPO: 2001-06-21
INMED PHARMACEUTICALS INC
1445-885 West Georgia St.
Vancouver BRITISH COLUMBIA V6C1B4 CA
CEO: Eric Adams
Employees: 0
Phone: 16046697207
INMED PHARMACEUTICALS INC / INM FAQ
What does INMED PHARMACEUTICALS INC do?
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
What is the current price of INM stock?
The current stock price of INM is 0.6916 USD. The price decreased by -9.12% in the last trading session.
What is the dividend status of INMED PHARMACEUTICALS INC?
INM does not pay a dividend.
What is the ChartMill technical and fundamental rating of INM stock?
INM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for INM stock?
INMED PHARMACEUTICALS INC (INM) currently has 0 employees.
Can you provide the market cap for INMED PHARMACEUTICALS INC?
INMED PHARMACEUTICALS INC (INM) has a market capitalization of 2.02M USD. This makes INM a Nano Cap stock.
What is the ownership structure of INMED PHARMACEUTICALS INC (INM)?
You can find the ownership structure of INMED PHARMACEUTICALS INC (INM) on the Ownership tab.